You are here:

  1. Home
  2. NICE Guidance
  3. Published Guidance

Rozanolixizumab for treating antibody-positive generalised myasthenia gravis

  • Technology appraisal guidance
  • Reference number: TA1155
  • Published:  20 May 2026
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

22732-Rozanolixizumab-for-Myasthenia-Gravis-V1.0-FEB2022-NON-CONF.pdf (nihr.ac.uk)

This page was last updated: 29 March 2022

Back to top